These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35887928)

  • 21. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis.
    Choi A; Koch M; Wu K; Chu L; Ma L; Hill A; Nunna N; Huang W; Oestreicher J; Colpitts T; Bennett H; Legault H; Paila Y; Nestorova B; Ding B; Montefiori D; Pajon R; Miller JM; Leav B; Carfi A; McPhee R; Edwards DK
    Nat Med; 2021 Nov; 27(11):2025-2031. PubMed ID: 34526698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants.
    Wang Z; Zhao Z; Cui T; Huang M; Liu S; Su X; Li G; Song T; Li W; Zhong N; Xu M; Yang X; Huang W
    Emerg Microbes Infect; 2022 Dec; 11(1):829-840. PubMed ID: 35230230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.
    Jin P; Guo X; Chen W; Ma S; Pan H; Dai L; Du P; Wang L; Jin L; Chen Y; Shi F; Liu J; Xu X; Zhang Y; Gao GF; Chen C; Feng J; Li J; Zhu F
    PLoS Med; 2022 May; 19(5):e1003953. PubMed ID: 35617368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC].
    Poh XY; Lee IR; Lim C; Teo J; Rao S; Chia PY; Ong SWX; Lee TH; Lin RJH; Ng LFP; Ren EC; Lin RTP; Wang LF; Renia L; Lye DC; Young BE
    Trials; 2022 Jun; 23(1):498. PubMed ID: 35710572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity of BNT162b2 vaccine booster against SARS-CoV-2 Delta and Omicron variants in nursing home residents: A prospective observational study in older adults aged from 68 to 98 years.
    Alidjinou EK; Demaret J; Corroyer-Simovic B; Labreuche J; Goffard A; Trauet J; Lupau D; Miczek S; Vuotto F; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Sobaszek A; Hober D; Hisbergues M; Puisieux F; Autran B; Yazdanpanah Y; Labalette M; Lefèvre G
    Lancet Reg Health Eur; 2022 Jun; 17():100385. PubMed ID: 35469147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine.
    Liwsrisakun C; Pata S; Laopajon W; Takheaw N; Chaiwong W; Inchai J; Pothirat C; Bumroongkit C; Deesomchok A; Theerakittikul T; Limsukon A; Tajarernmuang P; Niyatiwatchanchai N; Trongtrakul K; Chuensirikulchai K; Kasinrerk W
    Immun Ageing; 2022 May; 19(1):24. PubMed ID: 35610643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and Safety of Homologous and Heterologous Prime-Boost Immunization with COVID-19 Vaccine: Systematic Review and Meta-Analysis.
    Cheng H; Peng Z; Si S; Alifu X; Zhou H; Chi P; Zhuang Y; Mo M; Yu Y
    Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Homologous and Heterologous Boosting of the Chadox1-S1-S COVID-19 Vaccine With the SCB-2019 Vaccine Candidate: A Randomized, Controlled, Phase 2 Study.
    Costa Clemens SA; Milan EP; Sprinz E; Neto JC; Pacciarini F; Li P; Chen HL; Smolenov I; Pollard A; Clemens R
    Open Forum Infect Dis; 2022 Aug; 9(8):ofac418. PubMed ID: 36043184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and Immunogenicity of a Heterologous Booster of Protein Subunit Vaccine MVC-COV1901 after Two Doses of Adenoviral Vector Vaccine AZD1222.
    Cheng SH; Lin YC; Chen CP; Cheng CY
    Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
    Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y
    JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants.
    Lam JY; Ng YY; Yuen CK; Wong WM; Yuen KY; Kok KH
    Emerg Microbes Infect; 2022 Dec; 11(1):964-967. PubMed ID: 35275039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant.
    Zuo F; Abolhassani H; Du L; Piralla A; Bertoglio F; de Campos-Mata L; Wan H; Schubert M; Cassaniti I; Wang Y; Sammartino JC; Sun R; Vlachiotis S; Bergami F; Kumagai-Braesch M; Andréll J; Zhang Z; Xue Y; Wenzel EV; Calzolai L; Varani L; Rezaei N; Chavoshzadeh Z; Baldanti F; Hust M; Hammarström L; Marcotte H; Pan-Hammarström Q
    Nat Commun; 2022 May; 13(1):2670. PubMed ID: 35562366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early assessment of the safety and immunogenicity of a third dose (booster) of COVID-19 immunization in Chinese adults.
    Zhang Y; Yang Y; Qiao N; Wang X; Ding L; Zhu X; Liang Y; Han Z; Liu F; Zhang X; Yang X
    Front Med; 2022 Feb; 16(1):93-101. PubMed ID: 35122211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immunogenicity and safety of a booster vaccination with an inactivated severe acute respiratory syndrome coronavirus 2 vaccine in adults aged 18 to 59 years].
    Pan HX; Huang BY; Deng Y; Chu K; Hu JL; Zhu DD; Wu JL; Zhang L; Wang M; Huang WJ; Tan WJ
    Zhonghua Yi Xue Za Zhi; 2022 Jan; 102(4):279-285. PubMed ID: 35073677
    [No Abstract]   [Full Text] [Related]  

  • 35. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study.
    Ai J; Zhang Y; Zhang H; Zhang Q; Fu Z; Lin K; Song J; Zhao Y; Fan M; Wang H; Zhou Y; Chen X; Qiu C; Zhang W
    Emerg Microbes Infect; 2022 Dec; 11(1):639-647. PubMed ID: 35034582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
    Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
    Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Immunogenicity of the Inactivated COVID-19 Vaccine Booster in People Living with HIV in China.
    Yi Y; Han X; Cui X; Wang P; Wang X; Liu H; Wang Y; Zhu N; Li Y; Lin Y; Li X
    Vaccines (Basel); 2023 May; 11(6):. PubMed ID: 37376408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants.
    Lyke KE; Atmar RL; Dominguez Islas C; Posavad CM; Deming ME; Branche AR; Johnston C; El Sahly HM; Edupuganti S; Mulligan MJ; Jackson LA; Rupp RE; Rostad CA; Coler RN; Bäcker M; Kottkamp AC; Babu TM; Dobrzynski D; Martin JM; Brady RC; Frenck RW; Rajakumar K; Kotloff K; Rouphael N; Szydlo D; PaulChoudhury R; Archer JI; Crandon S; Ingersoll B; Eaton A; Brown ER; McElrath MJ; Neuzil KM; Stephens DS; Post DJ; Lin BC; Serebryannyy L; Beigel JH; Montefiori DC; Roberts PC;
    NPJ Vaccines; 2023 Jul; 8(1):98. PubMed ID: 37433788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant.
    Zang J; Yin Y; Xu S; Qiao W; Liu Q; Lavillette D; Zhang C; Wang H; Huang Z
    Front Immunol; 2022; 13():908478. PubMed ID: 35844601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.